Document Type

Contract Awards

Tender Summary

Exclusive Medicines With Active Ingredients Omalizumab, Secukinumab, Ruxolitinib, Eltrombopag, Canakinumab, Dabrafenib, Trametinib, Siponimod, Everolimus, Ofatumumab, Lapatinib, Dexamethasone/tobramyc

Action Deadline

15 Aug 2024